Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Sacituzumab Govitecan + Zimberelimab + Domvanalimab in Muscle Invasive Bladder Cancer
NCT06133517Phase 2Active, not recruiting
- Sponsor
- Fundación para el Progreso de la Oncología en Cantabria
- Start
- Jan 2025
- Primary completion
- Jan 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan, zimberelimab, domvanalimab in urothelial bladder carcinoma (UBC), sponsored by Fundación para el Progreso de la Oncología en Cantabria. Started Jan 2025; status: active, not recruiting.
02
Drugs
sacituzumab govitecanzimberelimabdomvanalimab
03
Conditions
urothelial bladder carcinoma (UBC)
Beyond the preview
Go deeper on NCT06133517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06133517.